Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours
Georgios K. Dimitriadis, Martin O. Weickert, Harpal S. Randeva, et al.
Endocrine Related Cancer (2016) Vol. 23, Iss. 9, pp. R423-R436
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

S2k-Leitlinie Neuroendokrine Tumore

Zeitschrift für Gastroenterologie (2018) Vol. 56, Iss. 06, pp. 583-681
Open Access | Times Cited: 164
Paraneoplastic endocrine syndromes
Georgios K. Dimitriadis, Anna Angelousi, Martin O. Weickert, et al.
Endocrine Related Cancer (2017) Vol. 24, Iss. 6, pp. R173-R190
Open Access | Times Cited: 78
Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies
Christoph J. Auernhammer, Christine Spitzweg, Martin K. Angele, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 6, Iss. 5, pp. 404-415
Closed Access | Times Cited: 66
Current best practice in the management of neuroendocrine tumors
Marina Tsoli, Eleftherios Chatzellis, Anna Koumarianou, et al.
Therapeutic Advances in Endocrinology and Metabolism (2018) Vol. 10
Open Access | Times Cited: 60
Waste Sludge: Entirely Waste or a Sustainable Source of Biocrude? A Review
Farin Tasnuva Dhara, Md. Atik Fayshal
Applied Biochemistry and Biotechnology (2024)
Closed Access | Times Cited: 6
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl
Lowell Anthony, Claire Ervin, Pablo Lapuerta, et al.
Clinical Therapeutics (2017) Vol. 39, Iss. 11, pp. 2158-2168
Open Access | Times Cited: 41
Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors
Sergio Pedraza‐Arévalo, Manuel D. Gahete, Emilia Alors‐Pérez, et al.
Reviews in Endocrine and Metabolic Disorders (2018) Vol. 19, Iss. 2, pp. 179-192
Closed Access | Times Cited: 41
Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification
Hirotaka Ishida, Alfred K. Lam
Critical Reviews in Oncology/Hematology (2019) Vol. 145, pp. 102835-102835
Open Access | Times Cited: 40
Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study
A Veltroni, E. Cosaro, Francesca Spada, et al.
European Journal of Endocrinology (2020) Vol. 182, Iss. 4, pp. 439-446
Open Access | Times Cited: 37
Management of Diarrhea in Patients With Carcinoid Syndrome
Boris G. Naraev, Magnus Halland, Daniel M. Halperin, et al.
Pancreas (2019) Vol. 48, Iss. 8, pp. 961-972
Open Access | Times Cited: 36
Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
Xi‐Feng Jin, Matilde Pia Spampatti, Christine Spitzweg, et al.
Reviews in Endocrine and Metabolic Disorders (2018) Vol. 19, Iss. 2, pp. 145-158
Closed Access | Times Cited: 30
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR
David Cella, Jennifer L. Beaumont, Stacie Hudgens, et al.
Clinical Therapeutics (2018) Vol. 40, Iss. 12, pp. 2006-2020.e2
Open Access | Times Cited: 30
When should genetic testing be performed in patients with neuroendocrine tumours?
Triona O’Shea, Maralyn Druce
Reviews in Endocrine and Metabolic Disorders (2017) Vol. 18, Iss. 4, pp. 499-515
Open Access | Times Cited: 29
Nutritional and vitamin status in patients with neuroendocrine neoplasms
Dominique Clement, Margot Tesselaar, Monique E. van Leerdam, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 10, pp. 1171-1184
Open Access | Times Cited: 29
Glucagonoma: From skin lesions to the neuroendocrine component (Review)
Florica Șandru, Mara Carşote, Simona Elena Albu, et al.
Experimental and Therapeutic Medicine (2020)
Open Access | Times Cited: 24
Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms
Krystallenia Alexandraki, Aggeliki Karapanagioti, Ioannis Karoumpalis, et al.
BioMed Research International (2017) Vol. 2017, pp. 1-12
Open Access | Times Cited: 28
Carcinoid Syndrome: Updates and Review of Current Therapy
Kira Oleinikov, Shani Avniel-Polak, David J. Gross, et al.
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 9
Closed Access | Times Cited: 23
Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes
Tetsuhide Ito, Robert T. Jensen
Expert Opinion on Pharmacotherapy (2020) Vol. 22, Iss. 6, pp. 685-693
Open Access | Times Cited: 22
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome
Martin O. Weickert, Gregory Kaltsas, Dieter Hörsch, et al.
Clinical Therapeutics (2018) Vol. 40, Iss. 6, pp. 952-962.e2
Open Access | Times Cited: 21
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
David Cella, Jennifer Evans, Marion Feuilly, et al.
Advances in Therapy (2021) Vol. 38, Iss. 2, pp. 969-993
Open Access | Times Cited: 14
Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients
Robert Fijalkowski, Dominik Reher, Anja Rinke, et al.
Neuroendocrinology (2021) Vol. 112, Iss. 6, pp. 547-554
Closed Access | Times Cited: 13
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors
Jennifer R. Eads, Diane Reidy‐Lagunes, Heloisa P. Soares, et al.
Pancreas (2020) Vol. 49, Iss. 9, pp. 1123-1130
Open Access | Times Cited: 14
Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome
Anna Koumarianou, Kosmas Daskalakis, Marina Tsoli, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 7
Closed Access | Times Cited: 8
Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours
Mfon Ewang-Emukowhate, Krithika Subramaniam, Francis Lam, et al.
Scandinavian Journal of Clinical and Laboratory Investigation (2023) Vol. 83, Iss. 8, pp. 576-581
Closed Access | Times Cited: 4
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome
Lowell Anthony, Matthew H. Kulke, Martyn Caplin, et al.
The Oncologist (2019) Vol. 24, Iss. 8, pp. e662-e670
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top